Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England - 17/09/24
, Tim Doran a, Michael G. Crooks b, Kamlesh Khunti c, Melissa Heightman d, Arturo Gonzalez-Izquierdo e, Muhammad Qummer Ul Arfeen e, Antony Loveless f, Amitava Banerjee e, Christina Van Der Feltz-Cornelis a, b, e
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Objectives |
This study examines clinically confirmed long-COVID symptoms and diagnosis among individuals with COVID in England, aiming to understand prevalence and associated risk factors using electronic health records. To further understand long COVID, the study also explored differences in risks and symptom profiles in three subgroups: hospitalised, non-hospitalised, and untreated COVID cases.
Methods |
A population-based longitudinal cohort study was conducted using data from 1,554,040 individuals with confirmed SARS-CoV-2 infection via Clinical Practice Research Datalink. Descriptive statistics explored the prevalence of long COVID symptoms 12 weeks post-infection, and Cox regression models analysed the associated risk factors. Sensitivity analysis was conducted to test the impact of right-censoring data.
Results |
During an average 400-day follow-up, 7.4% of individuals with COVID had at least one long-COVID symptom after acute phase, yet only 0.5% had long-COVID diagnostic codes. The most common long-COVID symptoms included cough (17.7%), back pain (15.2%), stomach-ache (11.2%), headache (11.1%), and sore throat (10.0%). The same trend was observed in all three subgroups. Risk factors associated with long-COVID symptoms were female sex, non-white ethnicity, obesity, and pre-existing medical conditions like anxiety, depression, type II diabetes, and somatic symptom disorders.
Conclusions |
This study is the first to investigate the prevalence and risk factors of clinically confirmed long-COVID in the general population. The findings could help clinicians identify higher risk individuals for timely intervention and allow decision-makers to more efficiently allocate resources for managing long-COVID.
Le texte complet de cet article est disponible en PDF.Keywords : Long COVID, Post SARS-CoV-2, Symptoms, Prevalence, Risk factor
Plan
Vol 89 - N° 4
Article 106235- octobre 2024 Retour au numéro
Article précédent
- Indirect effectiveness of a novel SARS-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: A cluster randomised analysis
- Asma Binte Aziz, Jonathan Dewing Sugimoto, Sye Lim Hong, Young Ae You, Lulu Bravo, Camilo Roa, Charissa Borja-Tabora, May Emmeline B. Montellano, Josefina Carlos, Mari Rose A. de Los Reyes, Edison R. Alberto, Milagros Salvani-Bautista, Hwa Young Kim, Irene Njau, Ralf Clemens, Florian Marks, Birkneh Tilahun Tadesse
- Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon
- Ayodele Alabi, Kossiwa Kokou, Saidou Mahmoudou, Ranmali Kavishna, Sravya S. Nakka, Sylvia Rothenberger, Fungai P. Musangomunei, Bisola F. Olubiyi, Juste C. Bie-Ondo, Anita L. Kabwende, Thirumalaisamy P. Velavan, VSV-EBOPLUS Consortium, Donata Medaglini, Helder I. Nakaya, Olivier Engler, Ali M. Harandi, Claire-Anne Siegrist, Peter G. Kremsner, Selidji T. Agnandji
Bienvenue sur EM-consulte, la référence des professionnels de santé.